Jove
Visualize
Contact Us

Related Experiment Videos

Interferon therapy for condylomatous vulvitis.

B J Horowitz1

  • 1Department of Obstetrics and Gynecology, Mt. Sinai Hospital, Hartford, Connecticut.

Obstetrics and Gynecology
|March 1, 1989
PubMed
Summary

Interferon alpha-2b recombinant effectively treated vulvar vestibulitis syndrome in patients with confirmed human papillomavirus (HPV). This safe and inexpensive therapy offers an alternative to more invasive treatments for vulvar pain.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Streptococcal vaginosis.

Journal of lower genital tract disease·2015
Same author

Vaginal lactobacillosis.

American journal of obstetrics and gynecology·1994
Same author

Evolving pathogens in vulvovaginal candidiasis: implications for patient care.

Journal of clinical pharmacology·1992
Same author

Mycotic vulvovaginitis: a broad overview.

American journal of obstetrics and gynecology·1991
Same author

Vulvar vestibulitis and vestibular papillomatosis. Report of the ISSVD Committee on Vulvodynia.

The Journal of reproductive medicine·1991
Same author

Antifungal therapy in the management of chronic candidiasis.

American journal of obstetrics and gynecology·1988
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Gynecology
  • Dermatology
  • Infectious Diseases

Background:

  • Vulvar vestibulitis syndrome is characterized by significant vulvar pain.
  • Human papillomavirus (HPV) has been implicated in some cases of vulvar vestibulitis.
  • Current treatments can be invasive and may not always be effective.

Purpose of the Study:

  • To evaluate the efficacy and safety of interferon alpha-2b recombinant for vulvar vestibulitis syndrome.
  • To determine if HPV is a prerequisite for successful interferon therapy.
  • To compare interferon treatment with placebo in patients with confirmed HPV.

Main Methods:

  • A 3-year study involving 30 patients with vulvar vestibulitis syndrome.
  • Colposcopy and biopsy were used to detect HPV.
  • Interferon alpha-2b recombinant was administered intradermally into the vestibule three times weekly for 4 weeks.
  • A subset of patients received placebo, followed by interferon retreatment if necessary.

Main Results:

  • HPV was detected in 17 out of 30 patients.
  • Fifteen patients treated with interferon experienced complete resolution of vulvar pain.
  • Patients without HPV did not respond to interferon.
  • Women with HPV responded to interferon, with post-therapy biopsies showing no evidence of the virus.
  • Placebo treatment was ineffective, but subsequent interferon retreatment was successful.

Conclusions:

  • Intradermal interferon alpha-2b recombinant is an effective and safe treatment for vulvar vestibulitis syndrome in patients with confirmed HPV.
  • HPV detection is crucial for identifying patients who will benefit from interferon therapy.
  • Interferon offers a less traumatic and potentially more cost-effective alternative to existing treatments for this specific patient group.

Related Experiment Videos